Abstract
The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Current Psychopharmacology
Title: Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Volume: 1
Author(s): Xiuping Chen, Jiajie Guo, Jiaolin Bao, Wenshan Xu, Yanjuan Huang and Yitao Wang
Affiliation:
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Abstract: The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Export Options
About this article
Cite this article as:
Chen Xiuping, Guo Jiajie, Bao Jiaolin, Xu Wenshan, Huang Yanjuan and Wang Yitao, Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010103
DOI https://dx.doi.org/10.2174/2211556011201010103 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress in Schizophrenia
Current Neuropharmacology Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets